MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study.

MLA

Szylberg, Mateusz, et al. “MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study.” Biomedicines, vol. 10, no. 8, Aug. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.3390/biomedicines10082030.

APA

Szylberg, M., Sokal, P., Śledzińska, P., Bebyn, M., Krajewski, S., Szylberg, Ł., Szylberg, A., Szylberg, T., Krystkiewicz, K., Birski, M., Harat, M., Włodarski, R., & Furtak, J. (2022). MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study. Biomedicines, 10(8), N.PAG. https://doi.org/10.3390/biomedicines10082030

Chicago

Szylberg, Mateusz, Paweł Sokal, Paulina Śledzińska, Marek Bebyn, Stanisław Krajewski, Łukasz Szylberg, Aneta Szylberg, et al. 2022. “MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study.” Biomedicines 10 (8): N.PAG. doi:10.3390/biomedicines10082030.